Introduction
Walking into 2026, vascular medicine has just experienced its most transformative year in a decade. Nearly every aspect of vascular care was rethought in 2025, propelled by rapid advances in clinical evidence and technology. Landmark trials in peripheral arterial disease, breakthroughs in venous interventions, and innovations in imaging and therapeutics have sharpened our tools and refined our strategies. What follows is an in-depth review of 2025’s key developments – going beyond the headlines to interpret how this new evidence will shape patient care.
(This blog is intended for a broad audience, including physicians, patients, and healthcare professionals. It maintains a professional tone while clearly marking technical points and referencing sources. All major findings are cited to their sources in the literature.)
New Evidence in Peripheral Arterial Disease (PAD) and CLTI
Endovascular vs. Surgical Revascularization: BASIL-2 and BEST-CLI
One of the most decisive advances came in treating chronic limb-threatening ischemia (CLTI) – the severe end of PAD marked by ischemic pain, ulcers, or gangrene. The BASIL-2 trial provided long-awaited clarity for CLTI patients requiring below-the-knee (infrapopliteal) revascularization. In this UK-led randomized trial, an endovascular-first strategy significantly improved amputation-free survival compared to open bypass surgery. By ~3–4 years follow-up, 53% of patients randomized to vein bypass had experienced major amputation or death versus only 43% of those treated endovascularly. In practical terms, median survival without limb loss was 4.4 years with endovascular therapy, compared to 3.3 years with bypass. Limb-related outcomes (like wound healing) were similar between groups, and 30-day morbidity was not different. The main driver of benefit was fewer deaths in the endovascular group. BASIL-2’s message is clear: for infrapopliteal CLTI, start with endovascular treatment whenever feasible.
These results dovetail with insights from the BEST-CLI trial, which was reported in late 2022 and continued to influence practice in 2025. BEST-CLI took a personalized approach: it separately analyzed CLTI patients with a good saphenous vein for bypass (cohort 1) and those without (cohort 2). In patients with an optimal vein conduit and predominantly femoropopliteal disease, bypass surgery showed a distinct advantage – 42.6% versus 57.4% rate of major limb events or death at ~3 years, favoring surgery. In other words, when anatomy and conduit are favorable, surgical bypass reduces the combined risk of amputation or death from ~57% down to ~43%. However, that advantage disappeared in more complex cases. In BEST-CLI cohort 2 (those lacking a good vein or with extensive tibial disease), outcomes were statistically similar between surgical and endovascular therapy. Taken together, BEST-CLI and BASIL-2 reinforce an “anatomy-first” approach: use bypass when an excellent vein and suitable anatomy exist, but favor endovascular techniques when they do not. The old debate of “endo-first vs open-first” is giving way to a patient-specific strategy – bypass for the right candidate, endovascular for the rest.
Breakthrough in Below-the-Knee Treatment: Life-BTK Trial
Another game-changer in 2025 was the LIFE-BTK trial, which may herald a new era for below-the-knee interventions. LIFE-BTK tested an Everolimus-eluting bioresorbable scaffold (Abbott’s Esprit BTK) against conventional balloon angioplasty in CLTI patients with infrapopliteal disease. At 2 years, the scaffold showed better efficacy dramatically: the composite primary endpoint (vessel patency with limb salvage) was 68.8% with the drug-eluting scaffold vs 45.4% with angioplasty – a hazard ratio of 0.48 favoring the scaffold. Restenosis was nearly cut in half (approx. 28.5% vs 48.2% incidence of binary restenosis) with the scaffold, and the need for repeat revascularization was markedly lower (only ~9.7% required target lesion reintervention at 2 years, versus 18.6% in the PTA group). Impressively, these benefits persisted even after the scaffold had largely dissolved by 24–36 months. This is the first time a below-knee device demonstrates such durable results, effectively providing a “drug-eluting stent” effect without leaving anything permanent behind. Clinicians are understandably excited – as one investigator put it, “the durability of this result has never been demonstrated with any BTK technology previously”. If these outcomes hold in broader practice, the Life-BTK scaffold could become a new standard for tibial CLTI, offering hope for improved long-term limb salvage.
Real-World CLTI Outcomes: Liberty 360° Registry
Randomized trials weren’t the only source of progress – real-world data also affirmed that modern techniques are improving CLTI outcomes once thought dismal. The Liberty 360° registry (including over 1,200 PAD patients from Rutherford class 2 claudication to class 6 CLI) released extended follow-up analyses in 2025. The results showed surprisingly positive long-term outcomes in patients treated with contemporary endovascular therapy. For example, at 3 years, the survival rate for the most severe CLI patients (Rutherford class 6) was around 62%, and freedom from major amputation was ~80%. These figures exceed what older studies predicted for CLI, suggesting that advanced endovascular revascularization is allowing patients to live longer and keep their limbs. Notably, even non-ambulatory, high-risk CLI patients had better-than-expected limb salvage when treated with aggressive endovascular strategies. In Liberty 360°, five-year limb salvage rates for Rutherford 4–6 patients substantially surpassed historical controls (earlier trials often projected >25% major amputation rates at 1 year for CLI, whereas Liberty showed ~90–95% freedom from amputation at 1 year, even in Rutherford 5–6). The takeaway is that when PAD and CLI are managed with today’s armamentarium – crossing chronic occlusions, debulking plaque, drug-coated adjuncts, etc. – patients do far better than the old pessimistic adage of “CLI = 50% mortality or major amputation at 1–2 years.” Modern endovascular therapy, in experienced hands, can achieve outcomes once thought impossible. This is encouraging news for patients and providers: limb loss can be prevented even in advanced disease, and survival is improving.
Optimizing Medical Therapy: Dual Pathway Inhibition (VOYAGER-PAD)
In 2025, medical management of PAD also became clearer. The cornerstone remains VOYAGER-PAD, the trial that established the benefit of adding low-dose rivaroxaban (2.5 mg BID) to aspirin after a revascularization. VOYAGER-PAD showed a significant reduction in major adverse limb and cardiovascular events with this dual pathway inhibition, and continued analyses reinforce its importance. In fact, 2025 substudies highlighted that the absolute benefit of rivaroxaban+aspirin is greatest in high-risk PAD patients – those with diabetes, prior interventions, multi-vessel or infrapopliteal disease, etc. These patients have higher baseline event rates, so the absolute risk reductions from therapy are larger. For example, patients considered “fragile” (elderly, low body weight, or reduced kidney function) derived a net benefit from rivaroxaban despite slightly higher bleeding, because their risk of limb/thrombotic events was so elevated. Similarly, PAD patients with concomitant CAD or those with extensive disease see meaningful risk reductions with the addition of rivaroxaban. Importantly, the bleeding risk with low-dose rivaroxaban remained modest and manageable in these analyses – there was no significant increase in intracranial or fatal bleeding in high-risk groups. The bottom line heading into 2026 is that dual antithrombotic therapy (rivaroxaban + aspirin) should be the default after limb revascularization, unless a patient’s bleeding risk is truly prohibitive. The data consistently show fewer heart attacks, strokes, acute limb ischemia, and amputations with this approach. In practice, that means vascular clinicians should continue to prioritize VOYAGER-PAD therapy – especially for diabetic PAD patients, those with prior stents/bypasses, and others at high risk – to improve long-term outcomes.
Drug-Coated Balloons: The Final Word from SWEDEPAD
The saga of paclitaxel-coated balloons and stents in PAD – once hailed as revolutionary, then clouded by safety concerns – reached a conclusion of sorts in 2025. The final results of the SWEDEPAD trials were presented, offering the most definitive data yet on whether paclitaxel devices improve patient-centered outcomes. In short, they do not. In SWEDEPAD 1 (CLI patients) and SWEDEPAD 2 (claudication patients), paclitaxel-coated angioplasty devices failed to show any reduction in amputations or improvement in quality of life compared to plain (uncoated) devices. Over long-term follow-up, major outcomes like wound healing and all-cause survival were no better with drug-coated technology. Paclitaxel devices initially reduced restenosis/reinterventions in claudicants at 1 year, but that difference vanished over time. Crucially, the feared mortality “signal” that caused so much controversy was not borne out in aggregate – by 5–7 years, overall survival was statistically similar between paclitaxel and plain balloon groups. (There was a transient finding of higher 5-year mortality in the claudication subgroup with DCBs, but this was not sustained at 7 years.) The key takeaway from SWEDEPAD is a sobering one: paclitaxel devices improve angiographic patency, but they failed to improve the outcomes that truly matter – limb salvage, functional status, or longevity. As a result, enthusiasm for drug-coated balloons in PAD has justifiably cooled. In practice, 2025 saw a more selective, cautious use of paclitaxel devices – reserved for cases where reducing restenosis is critical, and the patient’s life expectancy and conditions make it worthwhile. Simultaneously, there is renewed attention on alternative drug-delivery platforms (e.g. sirolimus-coated balloons or new polymers) entering trials. The field has learned that safety is paramount and that hard outcomes, not just patency, must be the benchmark for new PAD devices.
Atherectomy Under Scrutiny: Meta-Analysis of 300+ Studies
Atherectomy, the plaque debulking technique widely used in endovascular PAD interventions, came under fresh scrutiny in 2025. A comprehensive meta-analysis – spanning over 300 studies and presented at VEITH 2025 – attempted to clarify atherectomy’s track record. On the surface, the pooled outcomes looked acceptable: across 190 studies with data, 12-month primary patency averaged ~75.4%, target lesion revascularization ~15.6%, major amputation only ~1.7%, and mortality 2.8%. Distal embolization during atherectomy was reported at a low 2.2% on average. These results suggest that in “real world” usage, atherectomy can achieve good vessel patency and limb preservation, without obvious safety red flags. However, the meta-analysis also highlighted what many have long suspected: the evidence base is extremely heterogeneous and dominated by lower-level studies. Only ~6% of the papers were randomized trials; the vast majority were single-arm series or retrospective reports. Many cases involved adjunct therapies (balloons, stents, etc.), making it hard to isolate atherectomy’s true added benefit. The authors concluded that atherectomy appears safe and effective in appropriately selected patients, but they could not firmly conclude that it was superior to simpler treatments. They called for more trials – particularly to determine if plaque modification improves drug-delivery or long-term outcomes when used with drug-coated balloons or stents. In practical terms, 2025’s stance on atherectomy is pragmatic: it remains a useful tool in the toolbox, especially for heavily calcified lesions or in-stent restenosis, but it should not be a default for every case. Interventionists are urged to weigh the added cost, procedure time, and embolic risk of atherectomy against its unproven incremental benefit. Going forward, expect a more evidence-driven and selective use of atherectomy, reserving it for scenarios where its value is clear.
Advances in Venous Thromboembolism (DVT and PE)
DVT Treatment Revolution: Mechanical Thrombectomy and the CLOUT Registry
Major strides were made in 2025 in treating deep vein thrombosis (DVT), particularly large-clot iliofemoral DVT. Traditional anticoagulation has long been the mainstay, but post-thrombotic syndrome (PTS) remains a frequent, debilitating outcome. This year, evidence solidified around mechanical thrombectomy as a game-changer for preventing PTS. The CLOUT registry, the largest prospective study of mechanical thrombectomy (MT) for DVT (using the ClotTriever device), reported its 2-year outcomes – and the data are striking. Among 285 patients followed for 24 months, 81.5% of treated limbs had no signs of PTS at 2 years, compared to only 18.8% at baseline (before clot removal). In fact, the rate of moderate-to-severe PTS (Villalta score ≥10) plummeted from ~47% of patients at baseline to just 6.4% at 2 years post-thrombectomy. Venous flow and vessel patency were restored in >93% of treated segments on follow-up ultrasounds. Patients also reported major improvements in leg pain, swelling, and quality of life scores after the procedure. These real-world results suggest that physically removing clot from large veins can dramatically improve long-term outcomes and nearly eliminate severe PTS in many cases. It’s important to note that CLOUT enrolled “all-comers” – including patients with extensive chronic clot and those contraindicated to thrombolysis. The fact that even chronic DVT patients showed durable symptom relief underscores the power of clearing out venous obstructions.
Building on this, 2025 saw the completion of enrollment in the pivotal DEFIANCE trial, the first randomized trial comparing mechanical thrombectomy + anticoagulation versus anticoagulation alone for iliofemoral DVT. While final results are pending, early signals (from interim analyses and related studies) have been promising. Observers expect that DEFIANCE will show lower rates of PTS and better symptom improvement in the thrombectomy arm, potentially setting a new standard of care. If confirmed, 2026 could mark a shift where interventional treatment of large DVTs becomes routine to preserve vein function. Supporting this momentum, clinical guidelines are already evolving. The 2025 European Society guidelines gave a Class IIa recommendation to consider catheter-based (or mechanical) clot removal for iliofemoral DVT in appropriate patients. The era of “just anticoagulate and hope for the best” in extensive DVT may be drawing to a close. Instead, using advanced devices (like ClotTriever) to extract thrombus and prevent the crippling sequelae of PTS is increasingly recognized as an effective, safe strategy. For patients – especially young, active individuals with large DVTs – these advances mean a better chance to keep their veins open and avoid chronic pain, swelling, and ulcers.
Pulmonary Embolism (PE): Head-to-Head Trials Validate Intervention
In the realm of pulmonary embolism, 2025 provided the first high-quality comparisons of interventional therapy versus conventional approaches. Two landmark trials reported results:
- PEERLESS – which compared large-bore mechanical thrombectomy (using Inari’s FlowTriever) against catheter-directed thrombolysis (CDT) in intermediate-high-risk PE.
- STORM-PE – which compared mechanical thrombectomy (using Penumbra’s Lightning Flash) against anticoagulation alone in intermediate-risk PE.
The PEERLESS trial was especially anticipated, as it directly pitted a device-only approach against the standard of catheter thrombolysis for sizable PE. The primary outcome was a hierarchical win ratio combining death, intracranial hemorrhage, major bleeding, clinical deterioration, and ICU stay. The result was resoundingly in favor of mechanical thrombectomy: the win ratio was 5.0, p < 0.001, favoring the thrombectomy arm. In practical terms, PEERLESS showed that *patients treated with large-bore mechanical thrombectomy had significantly less frequent clinical deterioration and needed less ICU care, with no increase in bleeding, compared to those receiving thrombolysis. This validates an interventional strategy for PE when rapid clot removal is needed, or lytic drugs are risky. By avoiding fibrinolytics, the mechanical approach essentially eliminated intracranial hemorrhage risk while successfully preventing hemodynamic crashes. As a result, many PE specialists are now favoring thrombectomy for eligible patients (e.g., those with heavy clot burden, RV strain, or contraindications to lytics).
Meanwhile, the STORM-PE trial confirmed that even versus anticoagulation alone, a modern thrombectomy device can make a difference – albeit using a surrogate endpoint. STORM-PE found that removing the clot led to a greater reduction in the RV/LV diameter ratio at 48 hours compared to anticoagulation, indicating quicker relief of right heart strain. While long-term clinical outcome data from STORM-PE are still pending, the immediate hemodynamic benefit is clear. Notably, no safety issues emerged; mechanical thrombectomy achieved technical success in all cases with no device-related major complications.
The combined message from these PE trials is empowering: catheter-based interventions (especially large-bore aspiration thrombectomy) can stabilize patients faster and as safely as traditional therapy. They reduce the chances of a patient’s PE worsening or requiring intubation/vasopressors, and can shorten ICU stays. For clinicians, this means we now have Level 1 evidence to justify intervention in intermediate-risk PE – particularly in those who are crashing or cannot receive thrombolytics. As we head into 2026, expect PE response teams (PERTs) to increasingly deploy thrombectomy devices as first-line therapy for severe PE. It’s a powerful option when “watchful waiting” on anticoagulation feels inadequate, and thrombolysis is high-risk. With outcomes like those in PEERLESS, many patients can avoid prolonged ICU care and get on the road to recovery faster, all while avoiding the bleeding hazards of lytics.
Chronic Venous Disease: Stents and Varicose Veins
Iliac Vein Stenting: Durable Results and Emphasis on Timing
For patients with chronic venous outflow obstruction – such as iliac vein compression (May–Thurner syndrome) or post-thrombotic vein scarring – 2025 brought reassuring data on the long-term success of iliac vein stenting. Modern dedicated venous stents (e.g. Wallstent, Vici, Zilver Vena) have now been followed for several years, and their patency and clinical impact remain excellent. Large series and extended trials reported primary patency around 95–98% at 1 year, and mid-70s percentage primary patency at 5 years after iliac vein stent placement. For instance, one study noted a 5-year primary patency of ~70% and a secondary patency of ~77%, which is comparable to surgical bypass outcomes. These high patency rates translate into meaningful patient benefits: chronic venous ulcers heal in a majority of cases once obstructed veins are stented, and recurrence rates are low. In one representative cohort, 75% of venous leg ulcers were still healed at 5 years post-stenting, indicating durable relief of venous pressure. Edema and pain also markedly improve – a classic study by Neglén et al. showed complete relief of chronic venous pain in ~62% of patients and significant swelling reduction in one-third, after iliac stent placement.
A key insight from the 2025 analyses is that earlier intervention yields better outcomes in severe venous disease. Patients who had their iliac obstruction treated sooner (for example, after months of non-healing ulcers rather than many years) experienced faster and more complete ulcer healing at 2 years than those who had delayed stenting. This makes intuitive sense: prolonged venous hypertension causes irreversible tissue changes, so relieving the obstruction earlier can prevent some of that damage. Accordingly, experts are pushing for timely stenting in cases of severe iliac vein obstruction, especially when patients have active venous leg ulcers or debilitating symptoms. Rather than waiting through endless rounds of compression therapy, referring these patients for venographic assessment and possible stent treatment can significantly improve their 2-year wound-healing outcomes. Venous specialists now often say: “Treat the outflow lesion, and the ulcers will follow.” The 2025 data back that up, showing major improvements in ulcer healing (often >80% healed) once iliac inflow is corrected. With such high patency and low complication rates (iliac stenting carries minimal morbidity in experienced hands), the threshold to intervene has lowered. Moving forward, expect more aggressive identification of iliac vein stenosis (e.g., with intravascular ultrasound) in patients with advanced chronic venous insufficiency, and prompt stenting when criteria are met. Preserving mobility and quality of life in these patients is a priority, and the tools to do so have proven their worth.
Modern Varicose Vein Treatments: Equal Efficacy, Different Profiles
Varicose vein therapy continued to evolve in 2025, though in a subtler “maturing” fashion. We now have multiple endovenous options – thermal ablation (laser or radiofrequency), nonthermal glue (cyanoacrylate), and mechanochemical ablation (MOCA) – all competing to treat saphenous vein reflux. The consensus now is that all these modalities achieve excellent and roughly equivalent efficacy in closing refluxing veins, so the choice can be tailored to patient preference and anatomy. Studies consistently show high anatomical success rates across technologies. For example, one multicenter comparison reported complete vein closure rates of ~94–98% at 1 year for radiofrequency ablation (RFA), cyanoacrylate closure (CAC), and MOCA. (Some analyses do indicate MOCA might have a slightly lower mid-term closure probability than thermal techniques, but the differences are small.) What differs more are the side effect profiles: thermal ablation can cause more post-procedure pain or paresthesias (due to heat effect on nerves), whereas glue and MOCA avoid thermal injury but can have mild inflammatory reactions (glue can cause phlebitis or local irritation in a subset of patients, and MOCA can cause transient muscle cramping). A 2025 network meta-analysis confirmed that thermal ablations (laser/RFA) and glue achieved the best odds of vein closure and symptom improvement, with MOCA slightly lagging in efficacy, but thermal methods led to more minor nerve irritation and pain in recovery. Importantly, no method had concerning safety issues; all are minimally invasive with rapid return to normal activity.
Given these findings, the debate over “which treatment is best” has faded. Instead, clinicians focus on matching the technique to the patient. If a patient fears needles and tumescent anesthesia, glue or MOCA (which require none) might be favored. If a patient has very large veins or extensive reflux, some physicians still prefer thermal ablation for its long track record. For those who want to avoid wearing compression stockings after treatment, glue ablation is attractive (the FDA does not mandate post-procedure compression for glue). In summary, 2025’s stance is that all approved varicose vein interventions are effective – over 90% vein occlusion rates and significant quality-of-life improvements are seen with each, so the choice should be individualized. Factors like the patient’s pain tolerance, cosmetic concerns, insurance coverage, and the physician’s experience can guide the decision. The emphasis is on patient-centered care: since efficacy is uniformly high, we can select the modality that best fits a patient’s needs and expectations. This is a great win for patients – compared to the era of surgical vein stripping, today’s treatments are less invasive and almost uniformly successful, with durable relief of symptoms. As these techniques continue to be refined (and costs come down), more patients are accessing care for venous disease, improving productivity and comfort for countless individuals with varicosities.
Innovations in Imaging and Technology
AI-Assisted Vascular Ultrasound and Imaging
Better imaging begets better decisions – a theme we highlighted last year – and in 2025, it truly materialized with advances in artificial intelligence (AI) in vascular imaging. Duplex ultrasound, the workhorse for vascular diagnostics and surveillance, received an AI upgrade. Several centers and vendors rolled out AI-augmented duplex systems that can automatically analyze waveforms, classify Doppler signals, and even predict flow-limiting lesions. For example, machine learning models were applied to classify arterial waveforms (triphasic vs monophasic) and flag possible stenoses without the sonographer having to interpret everything in real-time. AI algorithms can also help map out tibial and pedal arteries in CLTI patients, stitching together ultrasound segments to give a roadmap of distal targets for bypass or endovascular treatment. This has been especially useful in planning distal bypass grafts or pedal loop interventions in CLTI, where knowing which tibial arteries are continuous to the foot is crucial. By automatically tracking and highlighting continuous arterial segments, AI duplex mapping saves time and reduces operator variability.
Another area AI is tackling is surveillance ultrasound interpretation. Traditionally, interpreting graft surveillance studies or stent follow-ups can be subjective. Now, AI tools are being developed to measure velocities and alert clinicians to changes that meet criteria for significant stenosis, standardizing the process. This “second reader” approach can reduce missed lesions and false alarms. According to reports, such AI integration reduces inter-operator variability and creates more consistent follow-up pathways. A Houston Methodist review noted that automated image interpretation by AI can improve diagnostic performance and workflow efficiency in vascular ultrasound. Early real-world use suggests that junior technicians armed with AI assistance can achieve nearly the same accuracy as veteran sonographers in grading disease, which could democratize access to high-quality vascular studies in more settings.
Beyond ultrasound, other imaging modalities also saw tech boosts. Advanced plaque imaging with MRI and CT is being combined with AI to better characterize plaque composition (e.g., distinguishing fibrous vs lipid vs calcified components). This could one day help predict which plaques are prone to complications or guide atherectomy vs angioplasty decisions. In peripheral arterial disease, researchers are exploring AI to quantify medial arterial calcification from plain films or CT scans, since heavily calcified arteries can impede revascularization. AI-driven calcium scoring may become a tool to choose adjunctive therapies (like orbital atherectomy for severe calcific disease).
All told, 2025 was the year that AI truly entered the vascular lab, not as hype but as practical assistive technology. It is being used to standardize duplex ultrasound readings, enhance plaque imaging, and reduce diagnostic errors. While still in early phases, the promise is significant: by 2026 and beyond, we anticipate AI will routinely help vascular specialists with diagnosis and treatment planning, making care more precise and personalized. The goal is not to replace the clinician or technologist, but to augment their capabilities – catching subtle changes, performing tedious measurements, and freeing experts to focus on decisions and patient counseling. Given the complexity of vascular disease, these tools come at a perfect time to handle the deluge of data and ensure no detail is overlooked in providing optimal care.
Musculoskeletal Embolization: Treating Arthritis with Embo-Therapy
Finally, 2025 saw the maturation of an exciting frontier at the intersection of vascular and musculoskeletal medicine: embolization therapy for osteoarthritis. Specifically, Genicular Artery Embolization (GAE) for knee osteoarthritis gained further credibility with new trial data and longer-term follow-up.
Last year, we discussed early promising results of GAE (embolizing the hypertrophic genicular artery branches in arthritic knees to reduce pain and inflammation). In 2025, those results were solidified:
- The multi-center GENESIS-II trial (Genicular Artery Embolisation for Knee Osteoarthritis) presented updated findings. By 12 months, over 60% of patients achieved significant clinical improvement (measured by WOMAC/KOOS pain scores) after a single GAE treatment. Pain relief tended to occur within weeks and was sustained for at least 1 year in the majority of responders. Safety remained excellent – no serious complications, just mild self-limited skin discoloration or transient aches in some patients.
- Early U.S. experience mirrored the above. A small American series reported that around 70–75% of treated knees had significant pain reduction by 6 months, and patients decreased their use of analgesics and injections post-embolization. These align with the international data and give U.S. physicians confidence in adopting GAE.
- The first sham-controlled trials of GAE also read out more fully. Notably, Bagla et al.’s randomized trial (GAE vs sham) continued to show that real embolization produced superior outcomes to a sham procedure. Patients who underwent genicular embolization had greater early pain reduction and functional gains than those who received a sham (placebo) intervention. This addresses the placebo effect concern and indicates GAE’s benefits are genuine when the procedure is properly performed (i.e., all aberrant neovessels embolized). Another trial in Japan comparing GAE to conservative management similarly found significant pain score improvements favoring embolization at 1 month.
- Crucially, long-term durability was affirmed by the Japanese cohort led by Dr. Yuji Okuno. In a mid-term analysis of GAE patients (some followed out to 2–3 years), the cumulative clinical success rate at 6 months was ~86%, and ~80% of patients were still responders at 3 years after treatment. In other words, the vast majority of patients who got better initially maintained substantial pain relief even 2–3 years down the line. This is remarkable for a disease as chronic as knee osteoarthritis. It suggests that a single embolization can reset the inflammation and pain cycle for an extended period in many patients. (About 20–30% did have some return of symptoms by 2–3 years, but these could potentially be retreated or managed otherwise.) Additionally, MRI studies in these patients showed reduced synovial hypertrophy and vascularity, correlating with the clinical improvements.
All these findings reinforce that GAE is a promising, minimally invasive option for knee OA, particularly for patients who are either not ideal surgical candidates or want to defer knee replacement. It doesn’t fix mechanical issues like large bone spurs or meniscal tears, but by attacking the inflammatory driver of pain (the hypervascular synovium), it can provide meaningful relief and improved mobility. Patients often report being able to walk longer and participate in activities they had given up, thanks to reduced pain and swelling.
GAE is still considered adjunctive (it’s typically done after conservative measures like physical therapy, NSAIDs, and injections have failed, and before opting for total knee replacement). But with mounting evidence, it’s moving closer to mainstream. Interventional radiologists have refined their technique – using either microspheres or particles (or even repurposed antibiotic particles like imipenem) as embolics – and have demonstrated near-100% technical success in catheterizing and embolizing the target genicular arteries. The procedure is usually outpatient and well-tolerated under moderate sedation.
Looking forward, ongoing studies like GENESIS-II will clarify the ideal candidates (current thinking: best results in patients with milder osteoarthritis, Kellgren-Lawrence grade 1–3, rather than bone-on-bone deformity). There is also research on whether temporary embolics (that resorb after a few weeks) versus permanent microspheres yield different outcomes. And in the U.S., a new randomized trial (MOTION trial) is comparing GAE to steroid injections to see which provides superior relief.
But even now, the data are compelling: targeted microvascular therapy can meaningfully reduce knee pain. By blocking abnormal neovessels, GAE appears to reduce synovial inflammation and angiogenesis, breaking the cycle of pain–inflammation–more pain. Over 80% of treated patients experience clinically significant pain relief in the months after the procedure, and a majority sustain it long-term. This opens a new avenue of hope for the millions with knee OA who are caught between failing conservative care and not ready for surgery.
Conclusion
As we conclude this whirlwind tour, one theme stands out: Vascular medicine in 2025 moved faster and shone brighter than at any point in the past decade. The year’s advances – from paradigm-shifting trials in limb ischemia, to groundbreaking devices for DVT and PE, to cutting-edge tech in imaging and embolotherapy – have armed us with stronger evidence and better tools than ever before. We now have clearer treatment pathways for complex problems: we know when to open an artery versus when to stent it, how to save a leg with drugs and balloons, and how to rescue a patient from a pulmonary embolus without exposing them to bleeding risk. We’ve learned that saving limbs is possible even in “unsalvageable” cases, that veins can be kept open to prevent disability, and that even osteoarthritic joints can be helped by an interventionist’s catheter. Science is catching up with art.
Our responsibility in 2026 and beyond is to translate this evidence into everyday practice. Guidelines will be updated, algorithms refined – but it falls to clinicians on the ground to implement these advancements for every eligible patient. This means embracing an anatomy-first approach in CLTI (offer each patient the revascularization that fits their disease pattern best), offering endovascular thrombectomy in DVT/PE where appropriate to prevent long-term harm, individualizing varicose vein care to patient needs, and utilizing new technology (from drug-eluting scaffolds to AI imaging) to improve outcomes. It also means continuing to focus on fundamental goals: saving lives, saving limbs, and preserving quality of life and mobility.
The pace of progress has been exhilarating – but the ultimate measure of success is patient benefit. As we incorporate these advances, we expect to see fewer amputations, less suffering from clots and ulcers, and more patients living active lives with intact circulations. That is the true reward of this transformative year. Here’s to 2026, armed with knowledge from 2025, and to continuously improving care in the ever-evolving world of vascular medicine.